Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Creasallis develops CreaTap, a patented "plug-and-play" antibody modification technology that improves the penetration of antibody-based drugs into solid tumours, applicable to monoclonal, bispecific, and antibody-drug conjugates. It serves biopharmaceutical companies developing oncology therapeutics and is also building its own suite of antibody therapeutics with enhanced tumour penetration.
3 investors
Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL). Its customers include EMS agencies, trauma hospitals, military, law enforcement, and veterinary practices.
3 investors
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
3 investors
Develops software tools for researchers to conduct scientific analysis and answer biological research questions. The company focuses on making research tools accessible and scalable for scientists.
3 investors
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
3 investors
Curie develops eco-friendly ingredients at the intersection of chemistry and biology as alternatives to legacy chemicals for consumer products. It partners with brands and ingredient manufacturers to supply biosolutions and greener chemistries across industries.
3 investors
Curve Bio builds Whole-Body Intelligence models from its Whole-Body Atlas, a molecular map of the body, to power blood tests that monitor organ health in chronic disease patients. The company works in molecular diagnostics and biotechnology, focused on more accurate patient monitoring.
3 investors
Helus Pharma (branded Cybin) is a clinical-stage biotech developing novel serotonergic agonist therapies for mental health conditions, with lead programs including CYB004 in Phase 2 trials for generalized anxiety disorder. The company builds proprietary drug development and delivery formulations aimed at treating psychiatric disorders.
3 investors
Cyfuse Biomedical develops a platform technology that builds three-dimensional tissues and organs from spheroids using its proprietary Bio 3D Printer. Its products include the Bio 3D Printer, an in vitro liver-function evaluation tool for drug discovery support, and regenerative-medicine 3D cell products made entirely from cells.
3 investors
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
3 investors
Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets. The company serves the life sciences research and drug development sectors.
3 investors
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
3 investors
DAAN Biotherapeutics develops T-cell immunotherapies for cancer, including TCR-T cell therapies, TCR-mimic T-cell engagers, and conditionally activated T-cell engagers targeting tumor-specific antigens. The company is building an immuno-oncology pipeline aimed at improving precision and reducing toxicity for patients with cancer.
3 investors
Darmiyan develops medical AI and brain imaging software for early detection and monitoring of neurodegenerative diseases, particularly Alzheimer's. The platform targets healthcare providers, patients, and pharmaceutical companies seeking to advance brain health and disease prevention.
3 investors
Data-Driven Bioscience develops Duoseq, a cancer genomics platform that performs simultaneous DNA and RNA analysis from a single sample, delivering comprehensive molecular profiling results in two days for use in clinical diagnostics and research.
3 investors
DSI provides scientific services for preclinical research, including implanted telemetry support, in vivo study execution, data analysis and reporting, and GLP validation. It serves researchers and laboratories conducting physiological studies such as cardiovascular and respiratory monitoring in animal models.
3 investors
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
3 investors
Deep Blue Biotech develops sustainable chemicals by re-engineering cyanobacteria to convert CO₂ into high-value molecules, using AI-driven metabolic modelling. Its products include an ocean-derived hyaluronic acid, targeting the cosmetics/ingredients and broader chemicals industry.
3 investors
DeepCure develops small molecule therapies for immune and autoimmune diseases, with pipeline candidates including an oral STAT6 inhibitor (DC-15442) and DC-9476 for conditions such as rheumatoid arthritis. The company works with academic researchers, including the Leeds Institute of Rheumatic and Musculoskeletal Medicine.
3 investors
Delfa provides always-on AI agents that automate patient recruitment and retention tasks for clinical research sites, handling outreach, prescreening calls, SMS reminders, and CTMS data entry. It serves clinical trial sites and site networks, offering custom-built AI agents overseen by medical doctors and AI engineers.
3 investors
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies. It focuses on oncology drug discovery and clinical development.
3 investors
Dendreon develops and manufactures cellular immunotherapies, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for prostate cancer patients. The company also provides cell therapy research, development, and contract manufacturing services to other companies bringing cellular therapies to market.
3 investors
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform. Its pipeline focuses on monogenic repeat expansion disorders such as Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington's disease.
3 investors
Diffuse designs proteins using AI models trained on experimental data collected through proprietary assays and software, delivering validated AI-designed proteins to partners.
3 investors